Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 [Yahoo! Finance]
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
Relay Therapeutics (NASDAQ:RLAY) was upgraded by analysts at Wells Fargo & Company to an "overweight" rating.
Will Relay Therapeutics (RLAY) Board Additions Signal a Shift in Commercialization Strategy? [Yahoo! Finance]
Relay Therapeutics (NASDAQ:RLAY) had its price target raised by analysts at Wells Fargo & Company from $4.00 to $6.00. They now have an "equal weight" rating on the stock.